RedHill Biopharma Ltd. (TASE: RDHL)reported that the United States Patent and Trademark Office has published notification of a Notice of Allowance for U.S. Patent Application Serial Number 12/918,310 entitled “Methods and Compositions for Treating Inflammatory Bowel Disease”, directed to RedHill’s RHB-104 indicated for the treatment of Crohn’s disease. The company...
Read more
Monthly Archives: November 2012
Tiltan Starts Phase 2 Pancreatic Cancer
Tiltan Pharma announced that it has enrolled the first U.S. patient, at White Plains Hospital in Westchester County N.Y., in a Phase 2 clinical trial of its anti-angiogenic product, TL-118, for the treatment of metastatic pancreatic cancer. The Phase 2 study is already ongoing in four major oncology centers in...
Read more